Correction to: Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis

Detalles Bibliográficos
Autores principales: Zhou, Qunfang, Wang, Xiaohui, Li, Ruixia, Wang, Chenmeng, Wang, Juncheng, Xie, Xiaoyan, Li, Yali, Li, Shaoqiang, Mao, Xianhai, Liang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522777/
https://www.ncbi.nlm.nih.gov/pubmed/35920933
http://dx.doi.org/10.1007/s00535-022-01910-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522777/
https://www.ncbi.nlm.nih.gov/pubmed/35920933
http://dx.doi.org/10.1007/s00535-022-01910-7

Ejemplares similares